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Abstract 
Backround: Trimethylaminuria is a rare metabolic condition characterised by an unpleasant smell 
resembling rotting fish. Currently, the only measure of treatment efficacy is urine Trimethylamine levels 
which do not always reflect the patient’s experience of symptoms. A literature review did not find a 
specific tool to assess treatment efficacy from the patient’s perspective. 
The aim of this study was to develop an assessment tool to provide a quantitative measure of treatment 
efficacy in patients diagnosed with TMAU before and after treatment and assess its acceptability 
(feasibility of use and face and content validity) to people living with TMAU. 
Design: Mixed methods - a modified, four-round Delphi by email and Semi-structured interviews 
conducted after clinical appointments. 
Participants: Delphi: Eight individuals living with TMAU from the TMAU forum, six medical 
consultants and four dieticians in Metabolic Medicine in four National Health Service hospitals in 
England. Semi-structured interviews: three patients with TMAU in two National Health Service 
hospitals, UK. 
Results: The assessment tool contains 27 items distributed across four domains: Odour characteristics 
with six items, Mental well-being with 13 items, Social well-being with five items and Health care 
professionals support with three items.  Semi-structured interviews: views on the content and design of 
the tool. 
Conclusion:   A co-produced tool was successfully developed and considered acceptable to people living 
with TMAU.  While further testing is needed to further evaluate the validity and reliability of the 
assessment tool, meanwhile the tool may serve as a prompt for questioning for clinicians diagnosing and 
treating TMAU. 
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A concise 1 sentence take-home message (synopsis) of the article, outlining what the reader learns 
from the article 
 
The reader will learn that it is feasible to co-produce an acceptable assessment tool measuring TMAU 
treatment efficacy from the patient’s perspective using sequential methods and steps of tool 
development.  
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Introduction  1 
Trimethylaminuria (TMAU), also known as Fish Odour Syndrome, is a rare metabolic and 2 
psychologically disabling condition where affected individuals emit a foul odor resembling the smell of 3 
rotting fish faeces or garbage (Messenger et al 2013).  4 
The true prevalence of this disorder is unknown (Shephard et al 2015). While primary TMAU is more 5 
prevelent, secondary cases of TMAU have been described in parts of the world affecting both genders 6 
(Wise et al 2011).  7 
In primary TMAU trimethylamine (TMA), which derives from the intestinal bacterial degradation of 8 
food rich in choline, lecithin and carnitine, is emited in urine, sweat, breath and other bodily secretions 9 
(Mackay et al 2011) due to a fault in Flavin monooxigenate 3 enzyme (FMO3) which otherwise 10 
converts TMA into odourless trimethylamine N-oxide (TMANO) (Shephard et al 2015). Conversaly, in 11 
secondary TMAU TMA is emited due to hormonal modulation, liver damage, renal disease or viral 12 
infection (Mitchell 1999). 13 
In the absence of physical symptoms, diagnosis of TMAU is established by measuring oxidising ratios 14 
of TMA and TMANO in urine (Mackay et al 2011) or genetic testing (Shephard et al 2015). 15 
Newerteless, diagnosis of the condition is challenging and an assumption can be made that it is a 16 
psychological problem (Shephard et al 2015). TMAU has been shown to negatively affect the 17 
psychological and social well-being of the affected individuals (Lateef and Marshall-Lucette 2017) and 18 
may result in depression, anxiety, social isolation, difficulties with employment (Shephard et al 2015) 19 
and potentially attempted suicide (Dolphin et al 1997).   20 
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Currently there is no cure for TMAU, however, life style changes such as reducing the dietry 1 
precursors of TMA are recommended as first line management of this condition (Messenger et al 2 
2013). The malodorous smell has been variously reported to be alleviated by antibiotics, laxatives, 3 
supplements of riboflavin, charcoal, copper chlorophyllin, shampoos, soaps with a pH between 5.5 & 4 
6.5 (Wise et al 2011). Psychological counselling from a specialist in a safe environment has been 5 
reported by people living with TMAU to play a vital part in the management of this condition (Lateef 6 
and Marshall-Lucette 2017, Fraser-Andrews et al 2003). Consequently, these treatments are 7 
recommended in consultation with a metabolic medicine team and its associated dietetics and 8 
counselling services. 9 
A number of articles highlight challenges in TMAU management due to the available treatment not 10 
being universally efficacious (Shephard et al 2015, Messenger et al 2013, Danks et al 1976). In clinical 11 
practice the only markers of treatment effectiveness e.g response to anibiotics, riboflavin are TMA and 12 
TMA/TMANO ratios and the suggested threshold for the detection of symptoms is TMA concentration 13 
of 18–20 μmol/mmol creatinine in urine (Mackay et al 2011), however, this do not always reflect the 14 
patient’s experience of symptoms. 15 
 16 
In these circumstances, an approach which focuses on patient-reported outcome measures (PROMs) 17 
and patient-reported experience measures (PREMs) may be more appropriate to inform future TMAU 18 
treatment outcomes pre and post intervention (Monmouth Partners 2014). PROMs and PREMs are 19 
reported to narrow the gap between the clinician’s and patient’s view of clinical reality as they 20 
participate in the design of care delivery themselves, a process which is also known as co-production 21 
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and sees patients and clinical staff as equal partners to optimise the best outcome for each individual 1 
patient’s journey (O’Connell et al 2018). 2 
In this context, the aim of this study was to develop an assessment tool to provide a quantitative 3 
measure of treatment efficacy in patients diagnosed with TMAU before and after treatment and assess 4 
its acceptability (feasibility of use and face and content validity) to people living with TMAU.  5 
Methods  6 
A mixed methods sequential study, in which equal weighting to qualitative and quantitative findings 7 
was given (Creswell and Clark 2017), was selected in the absence of primary research findings 8 
(Keeney et al 2011). This involved using a modified Delphi technique (Keeney et al 2011) and semi-9 
structured interviews (Silverman 2017) to determine face validity of the tool, its acceptability and 10 
comprehension of the questions. 11 
Study Setting  12 
The modified Delphi was conducted by email with eight people living with a diagnosis of TMAU who 13 
participate in an online forum (http://www.tmau.org.uk), five medical consultants and four dieticians 14 
who work in four centres for metabolic diseases in NHS hospitals in England. The interviews were 15 
conducted with three patients in two hospitals in a metropolitan region in the UK.  16 
Delphi study: Experts were recruited via two routes - by approaching metabolic clinicians known to the 17 
research team with a request to assist with the study and by approaching a representative from the 18 
TMAU forum located via internet searching, who gained an agreement with people with TMAU to 19 
email their contact details. They were then emailed the study information and gave consent to 20 
participate. 21 
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Interviews: Patients attending their TMAU-related outpatient appointment were approached by their 1 
metabolic consultants at the end of the appointment who explained the study, and gave a patient 2 
information sheet and expression of interest form which clinicians passed onto KR if completed by the 3 
patient. KR then contacted the patients to arrange an interview. Written consent to participate was 4 
gained prior to the interview being conducted. 5 
Data Collection  6 
The modified Delphi technique was conducted by email in four rounds between November 2016 and 7 
February 2017. In round one, the concepts of potential areas of impact of illness on a person formed 8 
initial domains of interest (Ritenbaugh et al 2011, Cleeland and Ryan 1994) (supplementary file 1) and 9 
participants were asked to list items which they thought would measure TMAU treatment efficacy 10 
within these domains. In round two, participants were asked to rate each individual item summarised 11 
by the researchers individually (from those collected in the first round) in terms of their perceived 12 
importance to measure treatment efficacy in TMAU on a low (0) to high (10) point scale of importance. 13 
In round three, participants were asked to rank each of the items within each domain in the order of 14 
their perceived importance from within the list of items provided to measure the effectiveness of 15 
TMAU treatment. In round four, participants were asked to comment on the draft content of the TMAU 16 
treatment efficacy patient self-report survey, that had been developed from analysis of round three, 17 
including listing any statements that they continued to have any concerns with, ranking the domains 18 
headings in order of relative importance and commenting on the clarity of the instructions and the 19 
layout of the tool.  20 
The interviews were conducted in-person (KR) between May and July 2017 straight after patients’ 21 
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clinical appointments. Interviews followed a topic guide that focused on three areas – the content of the 1 
proposed tool, ease of use of the tool, and feelings and comfort/discomfort with completing the tool.  2 
Open ended questions were asked to allow discussion with patients. The interviews were digitally 3 
recorded and transcribed verbatim. 4 
Prior to the interviews, the draft survey was piloted with two healthcare professionals (one working in a 5 
hospital trust pain department and one with a nursing educational background) to gain feedback on the 6 
appropriateness of the content, its layout and instructions and to reflect on the  interviewing process. 7 
This process was facilitated through maintaining a personal reflective diary and critical discussions 8 
with peers and resulted in altering some of the questions on the topic guide and their order.  9 
Data analysis  10 
The Delphi analysis was qualitative at each round and quantitative at round two, three and four. In 11 
round one, the items put forward by participants were grouped by aligning similar items and moving 12 
them into a relevant domain in a qualitative process. The language used by participants was maintained 13 
in the items to reflect the original content. The pool of items collected in round one was reduced by 14 
excluding items which were rated, in round two, below the 3rd quartile of the median by ≥ 70% of 15 
participants (Hsu and Sandford 2007). All remaining items were re-grouped thematically by two 16 
researchers (KR and MH). In round three, the pool of items in each domain was reduced further by 17 
excluding items ranked above the 3rd quartile of the median (Hsu and Sandford 2007). In addition, the 18 
retained items were: translated into statements to make sense for the patient completing the tool and to 19 
be measurable; moved between domains for best fit; and arranged in the order of their importance 20 
according to the rankings.  In round four, the order of the overarching domains was established 21 
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according to the rankings of the experts and a further qualitative process involved aligning similar 1 
items into grouped items and moving them into a relevant domain by researchers (KR and MH).  2 
A thematic analysis (Braun and Clarke 2006) of the qualitative data obtained from the interviews was 3 
undertaken by KR and MH and involved transcribing, familiarising with data (reading and listening), 4 
generating independent coding, indexing of transcripts and naming themes through an iterative process 5 
with any differences resolved through discussion.  6 
Results  7 
Delphi and semi-structured interview participants’ characteristics and respond rates are presented in 8 
Table 1. 9 
 10 
Generating items for the survey via the Delphi study 11 
Round one generated 265 items distributed across 12 domains (table 2) with the largest number of 12 
items in the ‘Odour affecting psychological well-being – affective’ and ‘Odour affecting social well-13 
being’ domains.  The 265 items were reduced to 76 items across 10 domains by matching them 14 
qualitatively to other items (see supplementary file 2 for the detail of item reduction). Through this 15 
process the Odour affecting Physical Well-Being, Spirituality and Whole Person domains were 16 
removed as separate entities and the 35 items from those domains assimilated into other domains where 17 
similar concepts were already covered. Two new domains: Health Care Professionals and Work & 18 
Finances were created.  19 
As the median scores for importance of all items in round two were above the 3rd quartile, the 76 items 20 
were reduced to 39 items by the qualitative method (supplementary file 3). However, one item ‘I feel 21 
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suicidal’ was added by the experts in this round thus resulting in 40 items carried forward to round 1 
three. Following round three, the forty items were reduced to 27, ten items quantitatively as the median 2 
scores for importance were above the 3rd quartile of the median and three items by matching 3 
qualitatively to other items. The number of domains was also reduced qualitatively from 10 to five. 4 
Four out of five items from the ‘Comments from others’ domain were moved to the 'Mental Well-being 5 
– affective’ domain. The remaining item from that domain and the items from the ‘Coping 6 
mechanism’, ‘Work/finance’, ‘Healthcare professionals’ were moved to a newly created ‘Functional 7 
well-being’ (supplementary file 4). 8 
In round four there was no further item reduction. However, the ‘affective and cognitive Mental Well-9 
being’ domains were merged as they were perceived as a single entity by the experts and the 10 
‘Functional Well-being domain’ name was changed to ‘Other aspects affecting your life’ as it better 11 
represented the items in that domain and the final order of domains and statements were formed. 12 
Feasibility, acceptability, face and content validity of the survey 13 
One theme ‘Need to measure TMAU impact and its challenges’ emerged in relation to the content of 14 
the tool and its impact on participants and one theme ‘Views on tool design with suggestions for minor 15 
refinement’ in relation to the tool’s design.  16 
Need to measure TMAU impact and its challenges  17 
Feedback on the content of the tool was encouraging. Participants suggested that the domains in the 18 
assessment tool reflected their experiences with TMAU. 19 
participant (2): ‘it does pin down the experience of having TMAU … it does cover the actual 20 
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smell itself and it covers the emotional affect that it has on people and yeah and it talks about 1 
the social effect which are the three main areas of TMAU’ 2 
 3 
However, it was highlighted that the assessment tool focused on the impact TMAU had on quality of 4 
life rather than on the treatment received. The participants noted that there is no cure and a limited 5 
choice of TMAU treatment thus suggesting that scores after treatment may not be different from scores 6 
before treatment. The participants emphasised the importance of support from healthcare professionals 7 
in the management of TMAU  8 
participant (1): ‘they can’t do anything anymore for me but it’s nice, like Dr X said today, ‘I’m 9 
really sorry I can’t do any more’ and just making that statement, helps me feel good’. 10 
     11 
All three participants agreed that the mental well-being domain was an important concept to measure, 12 
however, they presented a different level of concern about asking people with TMAU questions on this 13 
issue.  One participant was unconcerned personally, seeing it as potentially helpful to be able to express  14 
psychological issues: 15 
participant (3): ’I did not have any concerns about any of these questions and I understood why 16 
they are being asked. … I would have thought for some people it might be a relief to kind of get 17 
down and actually say that they do feel anxious or something like that’. 18 
 19 
On the other hand, another participant considered that such questions might produce a more ‘defensive’ 20 
response: 21 
participant (2): ‘You are not necessarily going to get honest answers from everyone or it may 22 
well upset some people a lot... some people would not be prepared to say yes I feel suicidal and 23 
some people may feel very guilty that they feel suicidal they are not even going to admit that 24 
(thinking)’ 25 
    26 
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All participants thought that the content in the social well-being domain was relevant and appropriate 1 
to be included: 2 
participant (3) ‘I think it’s good questions to ask because I think this disorder does have an 3 
impact on … on social relationships… and I think they are fair questions because you cover 4 
career and relationships’. 5 
     6 
The feedback relating to the content in the odour characteristics domain was also positive. All patients 7 
thought it was relevant and appropriate to be included: 8 
participant (1) ‘the first subsection, that was absolutely clear, I didn’t have any problem with 9 
any that’. 10 
     11 
During the interviews participants provided TMAU narratives relating to their difficulties with 12 
achieving a diagnosis, TMAU as an illness, their perceptions on the intensity and variability of smell, 13 
restrictions on life style, impact on mental well-being, negative reactions from others, support from 14 
others and perceived effectiveness of TMAU treatment. It appeared that these narratives were triggered 15 
by completing the assessment tool or the interview. 16 
Views on tool design with suggestions for minor refinement  17 
All participants provided positive feedback on the design of the assessment tool indicating no issue 18 
with its layout or length. 19 
Participants provided suggestions to improve the introduction section, scoring instructions and the use 20 
of asterisks. Consequently, the asterisks were removed and the instructions in each sub scale were 21 
improved to remind patients that the statements related to their experience with TMAU; one statement 22 
‘I am not tolerant of other attitudes’ was removed from the Mental well-being domain; and one 23 
TMAU treatment efficacy assessment tool 
 
14 
statement ‘the odour comes from a particular part of the body’ was added to the Odour characteristics 1 
domain. The refined instructions of the TMAU treatment efficacy tool are presented in figure 1, its 2 
questions in figure 2 and its scoring and completion guide in supplementary file 5. 3 
Discussion  4 
The TMAU treatment efficacy tool was co-produced by 18 experts: eight individuals living with 5 
TMAU, six medical consultants and four dieticians in four rounds of the Delphi process and tested with 6 
three patients. It consists of 27 items distributed across four domains: Odour characteristics with six 7 
items, Social well-being with five items,  Health care professionals support with three items and Mental 8 
well-being with 13 items which comprises 48 % of the tool’s content.  9 
The evidence from the interviews reflect the findings from the Delphi study and literature confirming 10 
that items in the assessment tool relate to TMAU disorder (Chalmers et al 2005, Kim et al 2017, 11 
Mackay et al 2011) and importantly suggest that the items relating to feelings of depression and suicide 12 
could be emotionally provoking and sensitive to measure (Blair 2015).  The evidence from the 13 
interviews also suggests that TMAU symptoms can vary from patient to patient.  It seems likely that 14 
the value of the assessment tool may lie in its use by clinicians and patients to aid discussion, on highly 15 
sensitive topics that might otherwise be difficult to assess in the clinic, when patients are noted to 16 
sometimes only send indirect signals regarding emotional expression and clinicians may have low 17 
awreness or a lack of training in this area (Goto and Takemura 2016). That said, screening of general 18 
hosptial patients for suicide risk has previously been received positively (Horowitz et al 2013).  In-19 
clinic or at-home completion could take place prior to a consultation to help inform this patient-20 
clinician decision making process, allowing tailoring of treatment plans to match an individual’s 21 
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response and preference and providing a framework to identify treatment outcomes which otherwise 1 
could go unrecognised (O’Connell et al 2018).  The tool as currently designed calls for assessment at a 2 
moment in time (Brown and Ryan 2003), which may be coterminous with a medical outpatient review; 3 
it is recognised that measurement over a period of time, in line with the measurement of similar 4 
constructs such as psychological well-being (Deiner and Biswas-Deiner 2008). 5 
Involving a heterogeneous sample of 18 experts (Hasson et al 2000) in the tool’s development met 6 
recommendations by Okoli and Pawlowski (2004) suggesting that 10 to 18 experts are sufficient to obtain 7 
a wide range of views and Sumison’s (1998) suggestion that 70% participant response rate is sufficient 8 
to maintain validity of study results. The response rate in first round of the Delphi study was 100% and 9 
over 75% in the remaining three rounds, however, more importantly the representation of TMAU 10 
individuals across all rounds was greater than the representation of other experts. The mixed methods 11 
approach also enabled gaining wider perspectives which would be beyond the scope of a single research 12 
method (Creswell and Clark 2017). Additionally, every effort was made to increase transferibilty of the 13 
findings and limiting the researcher’s influence during the process: the items were aligned so that they 14 
reflected the experts’ original language (DeVilles 2011). Furthermore, the experts were able to review 15 
the items interpreted by the researcher and comment on them in each round of the Delphi process (Hasson 16 
et al 2000). The transparency of data retrieval during the interviews was increased by a second researcher 17 
who read the transcripts and commented on the outcome of the analysis (Silverman 2017).  18 
Limitations 19 
Consensus levels in Delphi studies vary between 51% and 100% (Stewart et al 1999), therefore it was 20 
recognised that the existence of consensus or no consensus did not mean the correct answer would have 21 
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been found, however, statistical calculations were used to reduce items quantitatively (Hasson et al 2000). 1 
A larger sample size of participants in the interviews may have generated more refinement of the 2 
assessment tool. However, due to low prevalence of TMAU, the sample size needed to be realistic in 3 
terms of the recruitment and data analysis requirements in a specified time period. Diagnostic detail from 4 
our participants living with a diagnosis of TMAU was not colleacted as the Delphi participants were 5 
mainly health care professional from a small number of UK metabolic specialist centres thus describing 6 
any of their characteristics may enable them to be identified by others in the field. 7 
Conclusion  8 
The aspescts of feasibility, acceptability, face and content validity of the tool presented in this paper 9 
represents the first step in the process of the tool’s development. While further development is needed to 10 
address issues such as the time period being considered by the patient whilst completing the tool, and to 11 
test for the validity and reliability of the assessment tool, it may serve as a useful discussion prompt 12 
between clinicians and patients when diagnosing and treating TMAU. A patient centred approach in the 13 
outpatient’s clinic could yield more detailed information to target and tailor treatment strategies and 14 
acknowledge the psychosocial aspects of the condition from a patient perspective. Following refinement 15 
the tool could be useful in the measurement of effect in interventions focusing on treatment efficacy in 16 
TMAU, in multi-centre trials.  17 
 18 
 19 
 20 
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Table 1 Delphi participants’ charactersistics, Delphi reponse rates and semi-structured 
interviews patients’ characteristics. 
Delphi participants’ characteristics 
Experts 
Number of 
Experts 
% of Delphi 
participants 
Gender TMAU type 
People living with 
TMAU 
8 44 
  
Female 
Not collected 
Metabolic 
Medicine 
Clinicians 
6 33 
Not displayed 
as potentially 
identifying 
  
N/A 
Metabolic 
Medicine 
Dieticians 
4 22 N/A 
Delphi Response rates 
Round 
Number of 
Experts who 
responded 
Number of Experts 
who did not respond 
% of 
Respondents 
% of Non- 
respondents 
One 18 0 100% 0% 
Two 15 
3 (2 clinicians, 1 
dietician) 
83% 17% 
Three 14 
4 (2 clinicians, 1  
dietician, 1 person 
with TMAU) 
77% 13% 
Four 14 
4 (2 clinicians, 1 
dietician, 1 person 
with TMAU) 
77% 13% 
Semi-structured interviews patients’ characteristics 
Patients approached Patients participating  Gender TMAU type 
6 3 F Primary 
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Table 2 Initial pool items 
Source Domain 
No 
Domain Name  Number of 
Items 
generated 
by 
participants  
Cleeland and Ryan 
(1994) 
1 TMAU symptoms Domain 35 
 2 Odour intensity and severity  17 
Ritenbaugh et al 
(2011) 
3 Odour affecting Physical Well-Being  9 
 4 Odour affecting Social Well-Being  48 
 5 Odour affecting Psychological Well-Being-cognitive  23 
 6 Odour affecting Psychological Well-Being-affective  58 
 7 Spirituality  8 
 8 Whole person 18 
Delphy Experts 9 Comments from others 30 
 10 Coping mechanisms Domain  12 
 11 Health Care Professionals 3 
 12 Work/finance 4 
   Total 265 
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Figure 1 Trimethylaminuria (TMAU) treatment efficacy assessment tool instructions  
 
Patient Identification number:                                                  
 
Date: 
  
This is an assessment tool which aims to measure how a range of symptoms associated with TMAU 
affect you. This assessment is carried out before and after you receive treatment from your consultant 
at the hospital. 
 
Due to the potentially sensitive nature of questions, it is possible that you may experience some 
temporary distress arising from the completion of the questionnaire. In the event of any distress, you 
will be asked if you need a comfort break or if you prefer to stop completing the questionnaire. Should 
any distress arise, you will have support of your team at the hospital, who will also sign post you to 
services which can be contacted, if any distress continues after completing this questionnaire.  
 
Below there is a list of statements about those symptoms and their impacts which you may or may not 
experience. 
 
Please read each statement and circle a value between 0-10 where 0 indicates that you disagree 
completely with the statement at the moment of completing the assessment tool and 10 indicates that 
you agree completely with it.  
 
Example: - Where would you circle your score against this statement example?  
                                                       Disagree                                                                   Agree  
                                                      completely                                                              completely                                
                                                  ___________________________________________________      
 
 
I eat healthily 0 1 2 3 4 
 
6 7 8 9 10 5 
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Figure 2 Trimethylaminuria (TMAU) treatment efficacy assessment tool questions 
The first 6 statements relate to the aspects of the odour characteristics with regards to TMAU 
                                                                                                        Disagree________________________Agree 
The odour is unpleasant 0 1 2 3 4 5 6 7 8 9 10 
The odour is intense 0 1 2 3 4 5 6 7 8 9 10 
The odour is constant 0 1 2 3 4 5 6 7 8 9 10 
The odour comes from the whole body 0 1 2 3 4 5 6 7 8 9 10 
I can sometimes smell the odour myself 0 1 2 3 4 5 6 7 8 9 10 
Others state they experience the odour 0 1 2 3 4 5 6 7 8 9 10 
The following 13 statements relate to the aspects of your mental well-being with regards to TMAU   
                                                                                                        Disagree________________________Agree 
TMAU restricts the way I live my life 0 1 2 3 4 5 6 7 8 9 10 
I worry about negative reactions or comments from others 0 1 2 3 4 5 6 7 8 9 10 
I am not tolerant of other's attitudes 0 1 2 3 4 5 6 7 8 9 10 
I feel resentment towards TMAU 0 1 2 3 4 5 6 7 8 9 10 
I can not accept TMAU  0 1 2 3 4 5 6 7 8 9 10 
I feel anxious 0 1 2 3 4 5 6 7 8 9 10 
I feel ashamed or embarrassed 0 1 2 3 4 5 6 7 8 9 10 
I feel depressed 0 1 2 3 4 5 6 7 8 9 10 
I feel helpless or trapped 0 1 2 3 4 5 6 7 8 9 10 
I feel paranoid 0 1 2 3 4 5 6 7 8 9 10 
I feel suicidal 0 1 2 3 4 5 6 7 8 9 10 
I feel guilt or self-blame 0 1 2 3 4 5 6 7 8 9 10 
I do not feel positive 0 1 2 3 4 5 6 7 8 9 10 
The following 5 statements relate to the aspects of your social well-being with regards to TMAU    
                                                                                                         Disagree________________________Agree 
My social contact is limited 0 1 2 3 4 5 6 7 8 9 10 
I do not feel confident 0 1 2 3 4 5 6 7 8 9 10 
My relationships are adversely affected 0 1 2 3 4 5 6 7 8 9 10 
I feel my condition has adversely affected my job/career 0 1 2 3 4 5 6 7 8 9 10 
Other people avoid me 0 1 2 3 4 5 6 7 8 9 10 
Additional (optional) 3 statements relate to healthcare delivery. Please circle whether you disagree or 
agree 
I feel misunderstood by healthcare professionals                              Disagree         I do not know           Agree 
I feel supported by healthcare professionals                                      Disagree         I do not know           Agree 
I do not understand the role of medication/ 
/supplements/diet in the management of TMAU                               Disagree         I do not know           Agree 
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Supplementary file  1 Concepts of potential areas of impact of TMAU on a person  
Column 1 Column 2 Column 3 Column 4 
Domain Your comments on these 
domains e.g. you agree, 
you suggest alternative 
wording, you disagree with 
its inclusion 
Examples of items 
for the 
questionnaire 
Your suggestions 
for items for the 
questionnaire 
TMAU Symptoms   I smell 
I feel .... 
  
Smell intensity and 
severity 
      
Smell affecting Physical 
Well-Being 
  I felt drained. 
I was tired/I had no 
energy/I was 
exhausted. 
I felt depleted. 
I didn’t sleep well. 
  
Smell affecting Social 
Well- Being 
  I felt alone. 
I feel connected. 
  
Smell 
affecting Psychological 
Well-Being -cognitive 
  I was unable to 
focus. 
I couldn’t think 
clearly. 
I am forgiving. 
I have learned new 
things about 
myself. 
I feel empowered. 
  
Smell 
affecting Psychological 
Well- Being -affective 
  I was anxious 
about the future. 
I was depressed. 
I laugh. 
I am content. 
I am joyful. 
  
Spiritual Well- Being   I had no hope. 
I am on a spiritual 
path. 
I feel spiritual. 
  
Whole person   My life was a 
mess. 
I just kept doing 
the same thing over 
and over. 
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I was really stuck 
in some parts of 
my life. 
I feel more 
complete. 
I am awake. 
I am aware. 
I’m living my life 
to the fullest. 
Comments from others   Other people have 
told me … 
  
Your suggestions for other 
domains 
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Supplementary file  2 Items reduction in round 2 
 Items rated on a 10 
point scale where 1 
was extremely 
important and 10 was 
least important in 10 
Domains 
Median Quartile 
3 
Items 
rated 
below 
the 3rd 
quartile 
Percentage of 
participants 
who rated the 
item below the 
3rd quartile of 
the median 
importance 
score 
Items reduction through 
Qualitative analysis 
 1 TMAU symptoms 
n=6  
        
1 Smell experienced by 
others 
1 4.3 10.0 71.4 Merged with 58 
2 Smell oneself 2.5 4.8 10.0 71.4 I can smell myself 
3 The smell comes from 
specific areas of the 
body 
3 4.8 10.0 71.4 Extend of the odour 
 e.g. specific area or whole body 
4 The smell comes from 
the whole body  
3 5.0 11.0 78.6 Merged with 3                             
5 The smell follows  4 5.8 10.0 71.4 The smell ligers or persists  
6 The smell is unpleasant 
e.g. rotten fish 
1.5 4.8 10.0 71.4 The odour is unpleasant 
 2 Odour intensity and 
severity n=4  
        
7 Distance the smell can 
travel 
3 4.8 10.0 71.4 The smell can travel 
8 Smell frequency 1 2.8 10.0 71.4 Merged with 10 
9 Smell intensity 1.5 3.0 11.0 78.6 Smell intensity 
10 Smell varies with 
triggering factors  
1.5 3.8 10.0 71.4 Smell is constant or triggered 
 by particular factors 
 3 Odour 
affecting Physical Well-
Being n=2  
        
11 Energy level 4 6.5 10.0 71.4 Merged with 44 
12 Physical symptoms 
other than smell 
5 8.0 11.0 78.6 Excluded based on experts 
feedback 
 4 Odour 
affecting Social Well- 
Being n=10  
        
13 Avoidance by others 1 3.8 10.0 71.4 Avoidance by others 
14 Avoidance of other 
people 
1 2.0 11.0 78.6 Merged with 21 
15 Feeling supported by 
others 
2.5 6.3 10.0 71.4 Feeling supported by others 
16 Impact on confidence 1 2.5 10.0 71.4 Confidence 
17 Impairment of 
friendships 
1.5 3.8 10.0 71.4 Impairment of friendships 
 & intimate relationships 
18 Impairment of intimate 
relationships 
1 2.0 11.0 78.6 Merged with 17 
19 Feeling helpless or not 2.5 4.8 10.0 71.4 Merged with 51 
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20 Feeling isolated or not 1 2.8 10.0 71.4 Feeling isolated or not 
21 Limitations on social 
contact 
1 1.8 10.0 71.4 Limitations on social contact 
22 Worrying about other 
reacting to TMAU 
1 3.3 10.0 71.4 Merged with 33 
23 Avoidance of other 
people 
1 3.8 10.0 71.4 Excluded - already in social WB 
14 
24 Feeling of Resilience 4.5 7.0 12.0 85.7 Feeling of Resilience 
25 Feeling Strong 5 6.5 10.0 71.4 Merged with 24 
26 Having a purpose in life 4 5.0 11.0 78.6 Having a purpose in life 
27 Life limiting 3 6.5 10.0 71.4 Restricting the way my life 
is lived 
28 Resentment 3 5.0 11.0 78.6 Resentment 
29 Resignation to the 
condition 
2.5 6.5 10.0 71.4 Resignation to TMAU 
30 TMAU acceptance 1.5 4.8 10.0 71.4 Excluded - already in 
psychological well-being 
31 Tolerance of others' 
attitudes  
3.5 6.8 10.0 71.4 Tolerance of others' attitudes  
32 Worrying about others 
making comments 
2.5 6.8 10.0 71.4 Merged with 33 
33 Worrying about the 
reactions of others 
2 6.8 10.0 71.4 Worrying about the reactions 
 or comments of others 
34 Appreciating diagnosis 1 5.0 12.0 85.7 Merged with 73 
35 Blaming oneself 2.5 5.8 10.0 71.4 Merged with 42 
36 Burden of TMAU 3.5 6.8 10.0 71.4 Merged with 27 
37 Concern about the 
future 
1.5 5.8 10.0 71.4 Merged with 27 
38 Feeling anxious 1 5.5 10.0 71.4 Feeling anxious 
39 Feeling ashamed 1 5.0 10.0 71.4 Feeling ashamed or embarrassed 
40 Feeling depressed 1 5.5 10.0 71.4 Feeling depressed 
41 Feeling embarrassed 1 3.5 10.0 71.4 Merged with 39 
42 Feeling guilty 3 5.0 11.0 78.6 Feeling guilty or self-blame 
43 Feeling humiliated 1.5 7.5 10.0 71.4 Feeling humiliated 
44 Feeling lethargic 4 6.0 11.0 78.6 Feeling lethargic 
45 Feeling need to please 
others 
3.5 5.8 10.0 71.4 Feeling need to please others 
46 Feeling normal or 
abnormal 
1.5 4.5 10.0 71.4 Feeling normal  
47 Feeling ostracised 4 6.8 10.0 71.4 Merged with 9 
48 Feeling paranoid 1 5.0 10.0 71.4 Feeling paranoid 
49 Feeling scared 1 4.3 10.0 71.4 Merged with 10 
50 Feeling tearful 2.5 5.5 10.0 71.4 Merged with 10 
51 Feeling trapped 1 5.5 10.0 71.4 Feeling helpless or trapped 
52 Feeling understood or 
not 
2 5.0 11.0 78.6 Merged with 33 
53 Life limiting 1 4.3 10.0 71.4 Excluded - already in 
psychological 
 WB cognitive 27 
54 Living in the moment 5 6.0 12.0 85.7 Merged with 22 
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55 Positive experience  3.5 5.0 11.0 78.6 Feeling positive 
56 TMAU acceptance 1.5 5.0 11.0 78.6 Merged with 22 
57 Victimisation and 
bullying 
1.5 3.8 10.0 71.4 Merged with 58  
 7 Comments from 
others  Domain n=5  
        
58 Others feeling 
uncomfortable 
experiencing the smell  
1.5 4.5 10.0 71.4 Negative reactions of others 
59 Others making loud 
comments 
3 5.8 10.0 71.4 Merged with 58 
60 Others’ reactions 1.5 4.5 10.0 71.4 Merged with 58 
61 Relying on others’ 
reactions 
1.5 6.5 10.0 71.4 Merged with 58 
62 Shock in others 
experiencing the smell  
2.5 4.8 10.0 71.4 Merged with 58 
 8 Coping mechanisms 
Domain n=10  
        
63 Coping 1.5 5.8 10.0 71.4 Excluded as this is the name of  
the domain 
64 Controlling anxiety 
with medication 
2.5 6.0 11.0 78.6 Controlling negative impact with  
medication 
65 Controlling depression 
with medications 
2.5 6.0 11.0 78.6 Merged with 64 
66 Mental well-being 1 3.8 10.0 71.4 Used it to name Mental WB   
domain 
67 Seeking advice 
from healthcare 
professionals 
5 7.8 10.0 71.4 Merged with support from 
health care professionals 
68 Symptoms recognition 2.5 4.5 10.0 71.4 Symptoms recognition 
69 Use of medication to 
control psychological 
symptoms  
6 9.5 10.0 71.4 Merged with 72 
70 Use of medication to 
control physical 
symptoms 
5.5 10.0 14.0 100.0 Excluded based on experts 
feedback 
71 Use of supplements to 
control TMAU 
4.5 6.0 11.0 78.6 Use of supplements 
 to control TMAU 
72 Use of medication to 
control TMAU 
2.5 6.5 10.0 71.4 Use of medication 
 to control TMAU 
 9 Health Care 
Professionals Domain 
n=2  
        
73 Support from healthcare 
professionals 
3.5 4.8 10.0 71.4 Support from healthcare  
professionals 
74 Being understood by 
healthcare professionals 
3 4.0 11.0 78.6 Being understood by healthcare 
professionals 
 10 Work/finances 
Domain n=2  
        
75 Financial impact 1.5 5.5 10.0 71.4 Financial impact 
76 Impact on job/career 1 3.8 10.0 71.4 Impact on job/career 
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Supplementary file  3 Items reduction in round 3 
Items 
number  
Domain Name/Number of items  
Overall 
Rank 
Quartile 
3 
Items reduction through Quantitative and 
Qualitative analysis 
  
1 TMAU odour characteristic Domain 
n= 7 
      
1 
Extent of the odour (eg specific areas 
or whole body) 
4 5.5 The odour comes from the whole body 
2 I can smell myself 5  I can smell the odour myself 
3 The odour is unpleasant 1  The odour is unpleasant 
4 The smell lingers or persists  6  Statistically excluded as >5.5 
5 
Smell is constant or triggered by 
particular factors 
3  The odour is constant 
6 Smell intensity 2  The odour is intense 
7 The smell can travel 7  Statistically excluded as >5.5 
  
2 Odour affecting Social Well-Being 
Domain n=5 
      
8 Avoidance by others 4 4 Other people avoid me 
9 Confidence 2  I feel confident 
10 Feeling supported by others  5  Statistically excluded as >4 
11 
Impairment of friendships and intimate 
relationships 
3  
My friendships or intimate relationships are 
affected 
12 Limitations on social contact 1  My social contact is limited 
  
3 Odour affecting Mental Well-Being 
–cognitive  Domain n= 7 
      
13 Feeling of Resilience 6 5.5 Statistically excluded as >5.5 
14 Having a purpose in life 7  Statistically excluded as >5.5 
15 Resentment 4  I feel resentment towards TMAU 
16 Resignation to TMAU 4  I am resigned to TMAU 
17 Restricting the way my life is lived 1  TMAU restricts the way I live my life 
18 Tolerance of others' attitudes  3  I am tolerant of other's attitudes 
19 
Worrying about the reactions or 
comments of others 
2  
I worry about negative reactions or 
comments from others 
  
4 Odour affecting Mental Well- Being 
–affective Domain n=11 
      
20 Feeling anxious 2 8.5 I regularly feel anxious 
21 Feeling ashamed or embarrassed 1  I regularly feel ashamed or embarrassed 
22 Feeling depressed 3  I regularly feel depressed 
23 Feeling helpless or trapped 4  I regularly feel helpless or trapped 
24 Feeling guilt or self-blame 7  I regularly feel guilt or self-blame 
25 Feeling lethargic 10  Statistically excluded as >8.5 
26 Feeling normal 9  Statistically excluded as >8.5 
27 Feeling paranoid 5  I regularly feel paranoid 
28 Feeling need to please others 11  Statistically excluded as >8.5 
29 Feeling positive 8  I regularly feel positive 
30 Feeling suicidal 6  I regularly feel suicidal 
  
5 Functional Well-Being Domain 
n=10 
      
31 Negative reactions of others 1 7.75 Merged with 19 
32 Others state they experience the smell 2  Others state they experience the smell 
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33 
Controlling negative psychological 
impact with medication 
8  Statistically excluded as >7.75 
34 Symptoms recognition 4  Merged with 2 
35 Use of supplements to control TMAU   
This item was not ranked due to a mistake in 
the layout of the form therefore merged as 
Understanding the role of medications or 
supplements in the management of TMAU 
36 Use of medication to control TMAU   As in 35 
37 
Being understood by healthcare 
professionals 
5  
I feel misunderstood by health care 
professionals 
38 Support from healthcare professionals 6  
I feel supported from healthcare 
professionals 
39 Financial impact on earning potential 7  Statistically excluded as >7.75 
40 Impact on job/career promotion  3   
I feel my condition has adversely affected 
my job/career 
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Supplementary file  4 Final order of domains and statements  
  
Groupings from Round 
Three 
Statements in Round Four presented in 
new, shorter Domains Headings 
showing excluded items and grouped 
items 
Rank of the item in 
each domain  TMAU odour 
characteristic Domain  
TMAU odour characteristic  
1 The odour is unpleasant The odour is unpleasant 
2 Smell intensity The odour is intense 
3 
Smell is constant or 
triggered by particular 
factors 
The odour is constant 
4 
Extent of the odour (eg 
specific areas or whole 
body) 
The odour comes from the whole body 
5 I can smell myself 
I can smell the odour myself 
4 
Symptoms recognition - 
moved from functional  WB 
6 The smell lingers or persists  
Statistically excluded 
7 The smell can travel Statistically excluded 
  
Odour affecting Social 
Well-Being Domain 
Social Well-being  
1 
Limitations on social 
contact 
My social contact is limited 
2 Confidence I feel confident 
3 
Impairment of friendships 
and intimate relationships 
My friendships or intimate relationships 
are affected 
4 Avoidance by others Other people avoid me 
5 Feeling supported by others  Statistically excluded 
  
Odour affecting Mental 
Well-Being–cognitive  
Domain 
Mental Well-being  
1 
Restricting the way my life 
is lived 
TMAU restricts the way I live my life 
TMAU treatment efficacy assessment tool 
 
33 
1 Negative reactions of others 
I worry about negative reactions or 
comments from others  
2 
Worrying about the 
reactions or comments of 
others' 
3 
Tolerance of others' 
attitudes  
I am tolerant of other's attitudes 
4 Resentment I feel resentment towards TMAU 
4 Resignation to TMAU I am resigned to TMAU 
6 Feeling of Resilience Statistically excluded 
7 Having a purpose in life Statistically excluded 
  
Odour affecting Mental 
Well- Being –affective 
Domain   
1 
Feeling ashamed or 
embarrassed 
I regularly feel anxious 
2 Feeling anxious I regularly feel ashamed or embarrassed 
3 Feeling depressed I regularly feel depressed 
4 Feeling helpless or trapped I regularly feel helpless or trapped 
5 Feeling paranoid I regularly feel paranoid 
6 Feeling suicidal I regularly feel suicidal 
7 Feeling guilt or self-blame I regularly feel guilt or self-blame 
8 Feeling positive I regularly feel positive 
9 Feeling normal Statistically excluded 
10 Feeling lethargic Statistically excluded 
11 
Feeling need to please 
others Statistically excluded 
  
Functional Well-Being 
Domain  
Other aspects affecting your life 
1 Negative reactions of others moved to MWB cognitive 
2 
Others state they experience 
the smell 
Others state they experience the odour 
3 
Impact on job/career 
promotion  
I feel my condition has adversely effected 
my job/career 
4 Symptoms recognition moved to TMAU Characteristics 
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5 
Being understood by 
healthcare professionals 
I feel misunderstood by healthcare 
professionals 
6 
Support from healthcare 
professionals 
I feel supported by healthcare 
professionals 
7 
Financial impact on earning 
potential Statistically excluded 
8 
Controlling negative 
psychological impact with 
medication Statistically excluded 
These items were not 
ranked by all due to a 
mistake in the layout of 
the form  
Use of supplements to 
control TMAU 
Understanding of the role of medication or 
supplements in the management of 
TMAU 
Use of medication to 
control TMAU 
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Supplementary file  5 Refined Assessment Tool Completing and Scoring Guide 
 
 
Trimethylaminuria (TMAU) treatment efficacy assessment tool 
  
 
Patient Identification number:                                                  
 
Date: 
  
This is an assessment tool which aims to measure how a range of symptoms associated with 
TMAU affect you. This assessment is carried out before and after you receive treatment from 
your consultant at the hospital. 
 
Due to the potentially sensitive nature of questions, it is possible that you may experience 
some temporary distress arising from the completion of the questionnaire. In the event of any 
distress, you will be asked if you need a comfort break or if you prefer to stop completing the 
questionnaire. Should any distress arise, you will have support of your team at the hospital, 
who will also sign post you to services which can be contacted, if any distress continues after 
completing this questionnaire.  
 
Below there is a list of statements about those symptoms and their impacts which you may or 
may not experience. 
 
Please read each statement and circle a value between 0-10 where 0 indicates that you 
disagree completely with the statement at the moment of completing the assessment tool and 
10 indicates that you agree completely with it.  
 
Example: - Where would you circle your score against this statement example?  
                                                                Disagree                                               Agree  
                                                             completely                                        completely                                
                                                   _______________________________________________      
                                        
 
I eat healthily 0 1 2 3 4 
 
6 7 8 9 10 
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Beginning of the questionnaire 
The first 6 statements relate to the aspects of the odour characteristics with regards to TMAU 
                                                                                                                 Disagree_________________Agree 
The odour is unpleasant 0 1 2 3 4 5 6 7 8 9 10 
The odour is intense 0 1 2 3 4 5 6 7 8 9 10 
The odour is constant 0 1 2 3 4 5 6 7 8 9 10 
The odour comes from the whole body 0 1 2 3 4 5 6 7 8 9 10 
I can sometimes smell the odour myself 0 1 2 3 4 5 6 7 8 9 10 
Others state they experience the odour 0 1 2 3 4 5 6 7 8 9 10 
The following 13 statements relate to the aspects of your mental well-being with regards to TMAU   
                                                                                                               Disagree_________________Agree 
TMAU restricts the way I live my life 0 1 2 3 4 5 6 7 8 9 10 
I worry about negative reactions or comments from others 0 1 2 3 4 5 6 7 8 9 10 
I am not tolerant of other's attitudes 0 1 2 3 4 5 6 7 8 9 10 
I feel resentment towards TMAU 0 1 2 3 4 5 6 7 8 9 10 
I can not accept TMAU  0 1 2 3 4 5 6 7 8 9 10 
I feel anxious 0 1 2 3 4 5 6 7 8 9 10 
I feel ashamed or embarrassed 0 1 2 3 4 5 6 7 8 9 10 
I feel depressed 0 1 2 3 4 5 6 7 8 9 10 
I feel helpless or trapped 0 1 2 3 4 5 6 7 8 9 10 
I feel paranoid 0 1 2 3 4 5 6 7 8 9 10 
I feel suicidal 0 1 2 3 4 5 6 7 8 9 10 
I feel guilt or self-blame 0 1 2 3 4 5 6 7 8 9 10 
I do not feel positive 0 1 2 3 4 5 6 7 8 9 10 
The following 5 statements relate to the aspects of your social well-being with regards to TMAU    
                                                                                                                 Disagree_________________Agree 
My social contact is limited 0 1 2 3 4 5 6 7 8 9 10 
I do not feel confident 0 1 2 3 4 5 6 7 8 9 10 
My relationships are adversely affected 0 1 2 3 4 5 6 7 8 9 10 
I feel my condition has adversely affected my job/career 0 1 2 3 4 5 6 7 8 9 10 
Other people avoid me 0 1 2 3 4 5 6 7 8 9 10 
Additional (optional) 3 statements relate to healthcare delivery. Please circle whether you disagree or 
agree 
I feel misunderstood by healthcare professionals                               Disagree        I do not know         Agree         
Agree 
I feel supported by healthcare professionals                                       Disagree        I do not know         Agree       
Agree 
I do not understand the role of medication/ 
/supplements/diet in the management of TMAU                               Disagree         I do not know         Agree 
End of the questionnaire. Thank you. 
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Completing and Scoring Guide of the Trimethylaminuria (TMAU) treatment efficacy 
assessment tool 
 
This tool has been developed to assess whether the treatment offered to patients diagnosed 
with TMAU has worked when we consider a range of symptoms associated with TMAU and 
some of the impacts these may have on patients. The tool has been co-produced as part of a 
master’s dissertation by 2 researchers and 18 ‘experts’ in TMAU: people living with TMAU 
and clinicians (medical consultants and dieticians actively involved in the care of people with 
TMAU in England), using a Modified Delphi technique. This study was a collaboration 
between St George’s, University of London, Kingston University, Guy’s and St Thomas’ 
NHS Foundation Trust and University College London Hospitals NHS Foundation Trust. All 
intellectual property (IP) created relating to the Tool shall be jointly owned by the 
collaborators, but the Joint Research and Enterprise Office at St George’s University of 
London will lead on the management and exploitation of IP created during this project. 
  
Who is the tool for? 
 
Newly diagnosed patients with TMAU and those already diagnosed with TMAU who are 
commencing a new treatment regime. The assessment tool should be administered before the 
treatment commences and three months after the treatment commenced. Lower scores after 
completing the treatment indicate an improvement in symptoms, that is, can imply treatment 
efficacy. 
 
How do patients complete the tool? 
 
For each statement patients should circle a value between 0-10  
where 0 indicates they disagree completely with the statement at the moment of completing 
the assessment tool and 10 indicates that they agree completely 
 
How should the tool be scored? 
 
The 24 items on the scale are aggregated into the following 3 sub scales: 
 
 TMAU Odour Characteristics (6 items)  
 Mental Well-being (13 items)  
 Social Well-being (5 items)  
Each subscale is scored by summing the items completed within that scale. Any non 
completed item within each scale is to be recorded along with a reason for no completion. 
The subscales are not weighted – the sub scale score should only be viewed in relation to the 
potential best case and worst case scenario scores for each subscale as follows: 
Odour characteristics (6 items): Range 0 - 60 
Mental Well-being (13 items): range 0 - 130 
Social Well-being (5 items): range 0 - 50 
The overall TMAU scale is scored by summing scores across all 24 items, with a range of 0 – 
240. 
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Clinical importance of any decrease or increase in score 
 
The tool has not been fully validated and clinically important changes in scores have not been 
considered in the tool’s testing. It is for the patient and their clinician to interpret any changes 
in score and consider treatment options on the basis of this. 
Please note: If the patient answers yes to suicidal and depression feelings, please inform a clinician for 
appropriate referral. 
 
Healthcare delivery evaluation 
 
In addition, to the 24 items there are 3 items relating to health care evaluation. The scoring is 
only an indicator of healthcare delivery and is not included in the overall score of the TMAU 
treatment efficacy assessment tool.  
